CYTOMEGALOVIRUS (CMV) DNA AMPLIFICATION FROM PLASMA COMPARED WITH CMVPP65 ANTIGEN (PPUL83) DETECTION IN LEUKOCYTES FOR EARLY DIAGNOSIS OF SYMPTOMATIC CMV INFECTION IN KIDNEY-TRANSPLANT PATIENTS

Citation
Bz. Wirgart et al., CYTOMEGALOVIRUS (CMV) DNA AMPLIFICATION FROM PLASMA COMPARED WITH CMVPP65 ANTIGEN (PPUL83) DETECTION IN LEUKOCYTES FOR EARLY DIAGNOSIS OF SYMPTOMATIC CMV INFECTION IN KIDNEY-TRANSPLANT PATIENTS, Clinical and diagnostic virology, 7(2), 1996, pp. 99-110
Citations number
28
Categorie Soggetti
Virology
ISSN journal
09280197
Volume
7
Issue
2
Year of publication
1996
Pages
99 - 110
Database
ISI
SICI code
0928-0197(1996)7:2<99:C(DAFP>2.0.ZU;2-9
Abstract
Background: Rapid laboratory methods for the early detection of cytome galovirus (CMV) are needed for the prevention of CMV disease in transp lant recipients. These methods should not only be able to detect the v irus but also be highly predictive for CMV disease. Objective: The cli nical value of a simple and rapid nested plasma polymerase chain react ion (PCR) was evaluated by comparing the results with CMV pp65 antigen detection in leukocytes (CMV antigenemia assay), virus isolation from leukocytes, CMV IgG and IgM antibody response and clinical data. Stud y design: A total of 471 EDTA blood samples were collected from 85 kid ney transplant patients during a 3-4 month period after transplantatio n. CMV DNA was amplified directly from 10 mu l of plasma while 150 000 separated leukocytes were stained for CMV pp65 antigen by each of two monoclonal antibodies. A total of one million leukocytes were used fo r virus isolation. The PCR protocol used in the present study involves a simple alkaline lysis technique for isolating DNA directly from pla sma which is easy and rapid to perform. Results: Twenty-eight patients developed symptomatic CMV infection while asymptomatic infection occu rred in 29 patients. CMV pp65 antigen detection had a 75% sensitivity and a 57% positive predictive value for CMV disease development, compa red with 64% and 79% sensitivity and 49% and 46% positive predictive V alue for CMV DNA and viremia, respectively. The median time until dete ction of CMV in patients with symptomatic CMV infection was 26 days af ter transplantation, compared with 49 days in asymptomatic patients by any of the methods used. Early appearance (within 8 weeks) of CMV pp6 5 antigen and CMV DNA had high predictive values for symptomatic infec tion; repeated detection of pp65 antigen and CMV DNA were more common in symptomatic patients. Conclusions: CMV antigenemia assay and plasma PCR can be used for pre-symptomatic diagnosis of CMV infection. Virus isolation and CMV serology in most cases provide a post-symptomatic d iagnosis. The best marker for monitoring kidney transplant patients mi ght be the quantitative CMV antigenemia assay. (C) 1996 Elsevier Scien ce B.V.